Investigation of high gamma-glutamyltransferase syndrome in California Thoroughbred racehorses.
Authors: Peng Sichong, Magdesian K Gary, Dowd Joseph, Blea Jeffrey, Carpenter Ryan, Ho Wayne, Finno Carrie J
Journal: Journal of veterinary internal medicine
Summary
# Editorial Summary: High Gamma-Glutamyltransferase Syndrome in Racing Thoroughbreds Elevated serum GGT activity has long been observed in racing Thoroughbreds experiencing maladaptation to training, yet the cause has remained elusive—prompting researchers to investigate whether pancreatic dysfunction, oxidative stress, or genetic factors might underlie this condition. A cohort of 138 California racing Thoroughbreds with persistently elevated GGT (≥60 IU/L) were compared to unaffected controls across multiple parameters: pancreatic enzymes (amylase and lipase), vitamin E concentrations, and genome-wide genetic analysis. Surprisingly, affected horses showed no significant differences in pancreatic enzyme activity or α-tocopherol levels, and candidate gene screening of UGT1A1 and GGT1 proved uninformative; however, four single nucleotide polymorphisms clustered on chromosome 5 near the CD1A gene approached statistical significance (P = 2.15 × 10⁻⁵), suggesting a potential hereditary component related to immune regulation rather than the initially suspected metabolic defects. These findings tentatively indicate that high GGT syndrome may have a genetic basis analogous to heritable immune-related conditions documented in human medicine, shifting the investigative focus from acquired nutritional or pancreatic causes to constitutional variants affecting cellular differentiation pathways. For practitioners managing affected horses, this implies that environmental and training modifications alone may be insufficient; breeding selection and further investigation of immune competence in high-GGT animals warrant consideration.
Read the full abstract on PubMed
Practical Takeaways
- •High GGT levels in racing Thoroughbreds appear to have a genetic basis related to immune function rather than pancreatic disease or nutritional deficiency, suggesting screening and selective breeding strategies may be warranted
- •Elevated GGT should not be assumed to indicate pancreatic dysfunction in racehorses with maladaptation to training, as biochemical markers of pancreatic disease were not elevated in affected horses
- •Further investigation of CD1A1 and immune-related pathways may provide biomarkers or interventions for managing high GGT syndrome in racing populations
Key Findings
- •Serum lipase, amylase activity, and α-tocopherol concentrations did not differ between high GGT (≥60 IU/L) and control (<40 IU/L) horses, excluding pancreatic dysfunction and vitamin E insufficiency as primary etiologies
- •No genetic variants in candidate genes UGT1A1 and GGT1 were associated with high GGT phenotype
- •Four SNPs on chromosome 5 surrounding CD1A1 (cluster of differentiation 1a), a transmembrane gene related to major histocompatibility complex, approached suggestive association with high GGT syndrome (P = 2.15 × 10⁻⁵)